NO327819B1 - Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav - Google Patents

Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav Download PDF

Info

Publication number: NO327819B1
Authority: NO; Norway
Prior art keywords: riluzole; glutamate; pharmaceutically acceptable; cerebellum; acceptable salt
Prior art date: 1998-02-06

Application number

NO20003785A

Other languages

English (en)

Norwegian (no)

Other versions

NO20003785D0 (no

NO20003785L (no

Inventor

Alain Boireau

Andrees Bohme

Thierry Canton

Assunta Imperato

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-06

Filing date

2000-07-24

Publication date

2009-09-28

2000-07-24 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2000-07-24 Publication of NO20003785D0 publication Critical patent/NO20003785D0/no

2000-07-24 Publication of NO20003785L publication Critical patent/NO20003785L/no

2009-09-28 Publication of NO327819B1 publication Critical patent/NO327819B1/no

Links

FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title claims abstract description 20
229960004181 riluzole Drugs 0.000 title claims abstract description 19
150000003839 salts Chemical class 0.000 title claims abstract description 9
230000002265 prevention Effects 0.000 claims abstract description 6
206010008025 Cerebellar ataxia Diseases 0.000 claims abstract description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 19
229930195712 glutamate Natural products 0.000 claims description 19
238000002360 preparation method Methods 0.000 claims description 18
210000001638 cerebellum Anatomy 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 6
230000004064 dysfunction Effects 0.000 claims description 5
238000002560 therapeutic procedure Methods 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 3
208000015879 Cerebellar disease Diseases 0.000 abstract 1
108010078791 Carrier Proteins Proteins 0.000 description 10
239000004480 active ingredient Substances 0.000 description 6
210000003568 synaptosome Anatomy 0.000 description 6
241000700159 Rattus Species 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000002253 acid Substances 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229960003692 gamma aminobutyric acid Drugs 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
210000000449 purkinje cell Anatomy 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
235000019743 Choline chloride Nutrition 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
229960003178 choline chloride Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010000722 Excitatory Amino Acid Transporter 1 Proteins 0.000 description 1
108010000720 Excitatory Amino Acid Transporter 2 Proteins 0.000 description 1
102100031563 Excitatory amino acid transporter 1 Human genes 0.000 description 1
102100031562 Excitatory amino acid transporter 2 Human genes 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
102000034575 Glutamate transporters Human genes 0.000 description 1
108091006151 Glutamate transporters Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
VYEYJCBEXFTGBN-UHFFFAOYSA-N acetic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 VYEYJCBEXFTGBN-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
208000012268 mitochondrial disease Diseases 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000002966 varnish Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20003785A 1998-02-06 2000-07-24 Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav NO327819B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9801402A FR2774592B1 (fr)	1998-02-06	1998-02-06	Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr)	1998-02-06	1999-02-03	Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (3)

Publication Number	Publication Date
NO20003785D0 NO20003785D0 (no)	2000-07-24
NO20003785L NO20003785L (no)	2000-07-24
NO327819B1 true NO327819B1 (no)	2009-09-28

Family

ID=9522673

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20003785A NO327819B1 (no)	1998-02-06	2000-07-24	Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav

Country Status (18)

Country	Link
US (1)	US6245791B1 (de)
EP (1)	EP1052989B1 (de)
JP (1)	JP5127092B2 (de)
KR (1)	KR100574378B1 (de)
AT (1)	ATE245982T1 (de)
AU (1)	AU761978B2 (de)
CA (1)	CA2319686C (de)
DE (1)	DE69909970T2 (de)
DK (1)	DK1052989T3 (de)
EA (1)	EA002676B1 (de)
ES (1)	ES2199541T3 (de)
FR (1)	FR2774592B1 (de)
IL (2)	IL137608A0 (de)
NO (1)	NO327819B1 (de)
NZ (1)	NZ506124A (de)
PT (1)	PT1052989E (de)
WO (1)	WO1999039710A1 (de)
ZA (1)	ZA99740B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872739B1 (en) *	1999-06-04	2005-03-29	Vereniging Voor Christelijk Wetenshappelikjk Onderwijs	Use of riluzole for the treatment of multiple sclerosis
RS62915B1 (sr) *	2015-03-03	2022-03-31	Biohaven Therapeutics Ltd	Prolekovi riluzola i njihova primena
EP3706739B1 (de) *	2017-11-12	2024-10-16	Biohaven Therapeutics Ltd.	Verwendung von riluzolprodrugs zur behandlung von ataxien
SG11202011187QA (en) *	2018-05-27	2020-12-30	Biohaven Pharm Holding Co Ltd	Use of riluzole oral disintigrating tablets for treating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0374041B1 (de) *	1988-12-15	1992-06-17	Rhone-Poulenc Sante	2-Benzothiazolamin-Derivate enthaltende Arzneimittel, Verbindungen und ihre Herstellung
FR2700117B1 (fr) *	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) *	1993-03-05	1995-04-07	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) *	1994-01-12	1996-02-02	Rhone Poulenc Rorer Sa	Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) *	1994-10-26	1996-12-06	Rhone Poulenc Rorer Sa	Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

1998
- 1998-02-06 FR FR9801402A patent/FR2774592B1/fr not_active Expired - Fee Related
1999
- 1999-01-29 ZA ZA9900740A patent/ZA99740B/xx unknown
- 1999-02-03 CA CA002319686A patent/CA2319686C/fr not_active Expired - Lifetime
- 1999-02-03 NZ NZ506124A patent/NZ506124A/en not_active IP Right Cessation
- 1999-02-03 JP JP2000530209A patent/JP5127092B2/ja not_active Expired - Lifetime
- 1999-02-03 KR KR1020007008545A patent/KR100574378B1/ko not_active Expired - Fee Related
- 1999-02-03 PT PT99901703T patent/PT1052989E/pt unknown
- 1999-02-03 DK DK99901703T patent/DK1052989T3/da active
- 1999-02-03 ES ES99901703T patent/ES2199541T3/es not_active Expired - Lifetime
- 1999-02-03 EA EA200000816A patent/EA002676B1/ru not_active IP Right Cessation
- 1999-02-03 DE DE69909970T patent/DE69909970T2/de not_active Expired - Lifetime
- 1999-02-03 AT AT99901703T patent/ATE245982T1/de active
- 1999-02-03 IL IL13760899A patent/IL137608A0/xx active IP Right Grant
- 1999-02-03 EP EP99901703A patent/EP1052989B1/de not_active Expired - Lifetime
- 1999-02-03 WO PCT/FR1999/000230 patent/WO1999039710A1/fr not_active Ceased
- 1999-02-03 AU AU21711/99A patent/AU761978B2/en not_active Expired
2000
- 2000-07-24 NO NO20003785A patent/NO327819B1/no not_active IP Right Cessation
- 2000-07-31 IL IL137608A patent/IL137608A/en not_active IP Right Cessation
- 2000-08-03 US US09/631,798 patent/US6245791B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69909970D1 (de)	2003-09-04
AU2171199A (en)	1999-08-23
DK1052989T3 (da)	2003-11-17
FR2774592B1 (fr)	2000-03-17
ES2199541T3 (es)	2004-02-16
AU761978B2 (en)	2003-06-12
NO20003785D0 (no)	2000-07-24
ATE245982T1 (de)	2003-08-15
NZ506124A (en)	2003-07-25
JP5127092B2 (ja)	2013-01-23
WO1999039710A1 (fr)	1999-08-12
EP1052989B1 (de)	2003-07-30
US6245791B1 (en)	2001-06-12
IL137608A (en)	2006-09-05
PT1052989E (pt)	2003-12-31
ZA99740B (en)	1999-08-02
KR100574378B1 (ko)	2006-04-26
KR20010040671A (ko)	2001-05-15
CA2319686C (fr)	2009-06-23
EP1052989A1 (de)	2000-11-22
IL137608A0 (en)	2001-07-24
EA002676B1 (ru)	2002-08-29
NO20003785L (no)	2000-07-24
CA2319686A1 (fr)	1999-08-12
JP2002502819A (ja)	2002-01-29
FR2774592A1 (fr)	1999-08-13
DE69909970T2 (de)	2004-05-27
EA200000816A1 (ru)	2001-02-26

Legal Events

Date	Code	Title	Description
2014-09-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
JP5363152B2 (ja)	2013-12-11	グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
JP2025118661A (ja)	2025-08-13	遺伝性てんかん性障害の処置に使用するガナキソロン
KR101098209B1 (ko)	2011-12-23	운동성 질환에 걸린 환자의 치료 방법
Bartus et al.	2016	β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)
RS59048B1 (sr)	2019-08-30	Terapeutski agensi za neurodegenerativne bolesti
HUE024558T2 (hu)	2016-02-29	Biotin alkalmazása szklerózis multiplex kezelésére
EP2838530B1 (de)	2017-04-05	Verfahren zur behandlung von morbus parkinson
CA2454337A1 (en)	2004-08-06	Pharmaceutical compositions for the treatment of movement disorders
AU2017277005A1 (en)	2019-01-17	Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
Aguirre et al.	2023	Treatment of facioscapulohumeral muscular dystrophy (FSHD): a systematic review
Reginster et al.	2005	Current concepts in the therapeutic management of osteoarthritis with glucosamine
Meyer et al.	1998	Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil
CN111542314A (zh)	2020-08-14	神经退行性疾病的治疗剂
NO327819B1 (no)	2009-09-28	Anvendelse av riluzol eller et farmasoytisk akseptabelt salt derav
DRAGO et al.	1996	Vestibular compensation in aged rats with unilateral labyrinthectomy treated with dopaminergic drugs
JPH0276813A (ja)	1990-03-16	神経変性疾患の治療薬
AU2019288490A1 (en)	2020-12-03	Disease modifying methods for treating neurodegenerative diseases using nootropic agents
US20250127766A1 (en)	2025-04-24	Methods and compositions for treating cdkl5 disorder using monoamine oxidase inhibitors
Lichtigfeld et al.	1988	New vistas in chronic schizophrenia
CA3213592A1 (en)	2022-12-01	Antidepressant and anxiolytic substituted cinnamamide compound
Frier	1985	Therapeutic implications of modifying endogenous serotonergic analgesic systems
Grantham et al.	2003	Modulation of alpha 7 nicotinic receptors as a strategy for therapy in schizophrenia
Hertel et al.	2003	Blockade of glycine type-1 transporters augments NMDA receptor-mediated neuronal responses in vivo
JPWO1999053956A1 (ja)	2002-10-29	肥満症治療薬